All lobbying filings

Akin Gump Strauss Hauer & Feld

Akin Gump Strauss Hauer & Feld filed a Q1 report for Biotechnology Innovation Organization on April 20, 2026, reporting $60,000 in lobbying income.

Lobbying for Biotechnology Innovation Organization

As filed: AKIN GUMP STRAUSS HAUER & FELD for BIOTECHNOLOGY INNOVATION ORGANIZATION.

All filings by Akin Gump Strauss Hauer & Feld · Everything Biotechnology Innovation Organization has reported

Filing · LD-2 quarterly report Q1 report

Reporting period

1st Quarter 2026

Jan 1 - Mar 31 · Posted Apr 20, 2026

Income

$60,000

What the client paid this registrant for the period.

Client based in

District of Columbia

Official filing document

Government bodies contacted 2

The chambers, agencies and offices the filer named. It does not say who inside them was contacted, or when. Each name opens every filing that named the same body.

Lobbying activity 2

Health Issues

Issues related to Rare Pediatric Disease Priority Review Voucher Program reauthorization; Issues related to H.R. 1262/S. 3302 - Mikaela Naylon Give Kids a Chance Act of 2025; Issues related to the Consolidated Appropriations Act, 2026 (P.L. 119-75), including the extension of authority to issue priority review vouchers to encourage treatments for rare pediatric diseases.

Small Business

Issues related to the Small Business Innovation Research Program in S. 3971 - Small Business Innovation and Economic Security Act.

Bills named in this filing 3

H.R. 1262
Mikaela Naylon Give Kids a Chance Act
S. 3302
Mikaela Naylon Give Kids a Chance Act of 2025
S. 3971
Small Business Innovation and Economic Security Act

Source: federal Lobbying Disclosure Act filing, reproduced as filed. Bills are parsed from the activity descriptions.